The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Value Of The Tardive Dyskinesia Therapeutics Market Increase Between 2026 And 2030?
The tardive dyskinesia therapeutics market has seen robust expansion in recent years. It is anticipated to expand from $3.12 billion in 2025 to $3.35 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.4%. Historically, this expansion was driven by factors such as the limited available treatment options for tardive dyskinesia, the reliance on conventional antipsychotic management, low patient awareness, the increasing prevalence of antipsychotic use, and restricted access to specialty treatment centers.
The tardive dyskinesia therapeutics market size is set for significant expansion in the next few years. It is forecast to climb to $4.39 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.0%. This projected growth can be attributed to the advancement of novel treatments for tardive dyskinesia, a rise in research and development investment within neurological disorders, an increasing preference for homecare settings, the broadening of specialty treatment centers, enhanced patient monitoring, and the development of digital therapeutics. Key trends for the forecast period include the increasing adoption of deutetrabenazine and valbenazine, a heightened focus on personalized neurological therapy, the expansion of homecare and remote treatment options, growing awareness concerning drug-induced tardive dyskinesia, and an emphasis on safety and compliance in long-term treatment protocols.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24718&type=smp
What Influential Factors Are Boosting The Tardive Dyskinesia Therapeutics Market Demand?
The rising occurrence of mental health conditions is anticipated to drive expansion in the tardive dyskinesia therapeutics market in the future. These disorders are characterized by disruptions in an individual’s thoughts, feelings, conduct, or daily functionality, frequently leading to considerable discomfort or challenges in everyday living. The uptick in mental health disorders stems from growing social isolation, largely because the move towards digital interactions and rapid lifestyles has diminished valuable face-to-face relationships, contributing to heightened loneliness and emotional stress. Tardive dyskinesia therapeutics provide assistance to patients with mental disorders by controlling the involuntary movement symptoms that result from prolonged antipsychotic medication, consequently enhancing their commitment to treatment and their general well-being. As an illustration, data from 2024 by the National Alliance On Mental Illness, a US organization, indicates that approximately 600,000 yearly hospitalizations in the U.S. for individuals aged 18-44 are attributable to psychosis spectrum and mood disorders. Consequently, the growing occurrence of mental health conditions acts as a significant driver for the tardive dyskinesia therapeutics market.
What Key Segment Areas Are Included In The Tardive Dyskinesia Therapeutics Market Assessment?
The tardive dyskinesia therapeutics market covered in this report is segmented –
1) By Drug: Deutetrabenazine, Valbenazine, Other Drugs
2) By Product Type: Solid Dosage Forms, Tablets, Capsules, Liquid Dosage Form
3) By Application: Antipsychotic-Induced Tardive Dyskinesia, Other Drug-Induced Tardive Dyskinesia, Idiopathic Tardive Dyskinesia
4) By End-User: Hospitals, Clinics, Specialty Treatment Centers, Homecare Settings
Subsegments:
1) By Deutetrabenazine: Dosage Forms, Line Of Therapy, Distribution Channel
2) By Valbenazine: Dosage Forms, Patient Age Group, Distribution Channel
3) By Other Drugs: Drug Class Or Type, Dosage Forms, Treatment Duration
Which Trends Are Expected To Shape The Tardive Dyskinesia Therapeutics Market?
Key players within the tardive dyskinesia therapeutics market are concentrating on creating innovative products, including once-daily treatment options, which aid in sustaining more stable drug concentrations within the body. These once-daily treatment choices are defined as medicines or therapies intended for a single daily administration, thereby streamlining dosing regimens and enhancing patient compliance. An example of this is seen in May 2024, when Teva Pharmaceutical Industries Limited, an Israel-based biopharmaceutical firm, publicized the U.S. Food and Drug Administration (FDA) clearance for its AUSTEDO XR tablets, intended for managing tardive dyskinesia (TD) and Huntington’s disease (HD) chorea in adults. This recent approval of AUSTEDO XR provides patients with demonstrated efficacy in controlling involuntary movements, coupled with the convenience of a once-daily, single-pill dose. The novel formulation delivers therapeutic doses at a clinical level, as corroborated by pivotal clinical studies. Furthermore, it is currently offered in four distinct tablet strengths: 30 mg, 36 mg, 42 mg, and 48 mg.
Who Are The Firms Contributing To The Tardive Dyskinesia Therapeutics Market Ecosystem?
Major companies operating in the tardive dyskinesia therapeutics market are Neurocrine Biosciences Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Lundbeck A/S, Mitsubishi Tanabe Pharma Corporation, AbbVie Inc., Pfizer Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Ltd., Lupin Limited, Amneal Pharmaceuticals Inc., Lannett Company Inc., Alembic Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals PLC, Accord Healthcare Ltd., Cipla Ltd., Glenmark Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Indivior PLC, Viatris Inc., Alkem Laboratories Ltd., Intas Pharmaceuticals Ltd., Som Biotech Ltd., Addex Therapeutics Ltd., Luye Pharma Group Ltd., Apotex Inc., Sandoz Group AG, Torrent Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Taro Pharmaceutical Industries Ltd., Cadila Pharmaceuticals Ltd.
Access The Complete Tardive Dyskinesia Therapeutics Market Report:
Which Region Stands As The Largest Contributor To The Tardive Dyskinesia Therapeutics Market?
North America was the largest region in the tardive dyskinesia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tardive dyskinesia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Tardive Dyskinesia Therapeutics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24718&type=smp
Browse Through More Reports Similar to the Global Tardive Dyskinesia Therapeutics Market 2026, By The Business Research Company
Leukemia Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report
Bipolar Disorder Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/bipolar-disorder-therapeutics-global-market-report
Peptide Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model